生物治疗后皮肤T细胞淋巴瘤的发展：系统评价
Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review
影响因子:8.80000
分区:医学1区 Top / 皮肤病学1区
发表日期:2023 Mar
作者:
Lauren Schaefer, Nneka Comfere, Olayemi Sokumbi
摘要
生物治疗后皮肤的T细胞淋巴瘤极为罕见。该系统评价的目的是研究生物学剂治疗后皮肤T细胞淋巴瘤（CTCL）的发展。暴露于生物治疗后开发CTCL的患者进行了系统文献综述。作品仅限于英语，并排除了动物研究，指南和方案。使用受控词汇与关键词同时使用受控的词汇来识别潜在的合格标题。搜索策略在执行前进行了同行评审。二十八名研究显示，接触生物学剂后，有62名患者患有CTCL。其中44％是高加索人，诊断时的中位年龄为56岁。 76％的患者接受了原发性炎症性皮肤病的生物疗法。 Dupilumab是该队列中报道最多的（42％）的代理。在这些情况下，从生物学剂启动到CTCL诊断的中位时间为4个月（范围：0-84）。真菌病真菌（65％）和Sézary综合征（10％）是CTCL诊断的最常见亚型。据报道，有21名患者（34％）（34％）（34％），有21名（34％）患者的患者没有报告，有8名患者（16％）还活着并且完全缓解，疾病死亡，两名患者死亡，其他原因（3％）死亡。数据库）需要发生。
Abstract
Cutaneous T-cell lymphoma following biologic therapy is extremely rare.The aim of this systematic review was to investigate the development of cutaneous T-cell lymphoma (CTCL) following treatment with a biologic agent.A systematic literature review was performed for patients who developed CTCL after exposure to biologic therapy. Works were limited to English language and excluded animal studies, guidelines, and protocols. Potentially eligible titles were identified using controlled vocabulary in tandem with key words. The search strategy was peer-reviewed prior to execution.Twenty-eight total studies revealed sixty-two patients who developed CTCL following exposure to a biologic agent. Of these, 44% were Caucasian, and the median age at diagnosis was 56 years. Seventy-six percent of patients received biologic therapy for a primary inflammatory skin condition. Dupilumab was the most reported (42%) agent amongst the cohort. The median time from initiation of the biologic agent to diagnosis of CTCL in these cases was 4 months (range: 0-84). Mycosis fungoides (65%) and Sézary syndrome (10%) were the most common subtypes of CTCL diagnosed. Twenty-one (34%) patients were reported to be alive with disease, outcome was not reported in 21 patients (34%), ten patients (16%) were alive and in complete remission, eight patients (13%) died of disease and two patients (3%) died due to other causes.While biologic agents may have a role in the development of CTCL, in order to definitively elucidate their role, more methodologically robust studies (such as those that utilize population databases) would need to occur.